Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

  • HOME
  • BROWSE ARTICLES
  • Previous issues
17
results for

Previous issues

Article category

Keywords

Previous issues

Prev issue Next issue

Volume 31(4); October 2025

CMH Bulletin

The Liver Week 2025 Highlights: Celebrating the 30th Anniversary of the Korean Association for the Study of the Liver
Young Eun Chon, Ju Hyun Shim, Joo Hyun Oh, Jiwon Yang, Hyunjae Shin, Wonseok Kang, Yeongseok Hwang, Su Jong Yu, Jongman Kim, Hae Won Lee, Yoon Jun Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2025;31(4):1107-1114.
Published online October 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.1062

Citations

Citations to this article as recorded by  Crossref logo
  • Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
    Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee
    Cancer Immunology, Immunotherapy.2026;[Epub]     CrossRef
  • 3,922 View
  • 86 Download
  • 1 Web of Science
  • Crossref

Reviews

Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance
Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke
Clin Mol Hepatol 2025;31(4):1115-1138.
Published online June 9, 2025
DOI: https://doi.org/10.3350/cmh.2025.0541
Mendelian randomization (MR), a powerful statistical tool for causal inference, has been widely applied in various fields of medical research, even extending to economics and psychology. In hepatology, MR has been utilized to identify risk factors and potential therapeutic targets for liver diseases, including metabolic dysfunction-associated steatotic liver disease, cholestatic and autoimmune liver diseases, and hepatobiliary cancer. MR can provide evidence of causation via associations between genetic variants, modifiable exposures and liver disease occurrence or outcomes, using large existing datasets. However, results from MR studies are sometimes scattered, biologically not plausible or even controversial between analyses, potentially reflecting a trend of inappropriate application of this method (e.g., inappropriate selection of genetic instruments, insufficient assessment of horizontal pleiotropy, compromised statistical power, and neglected genetic diversity among different populations), and thus hinder the translation of MR findings from bench to bedside. Assessing these critical issues and pinpointing bona fide evidence are essential but quite challenging for clinicians. In this review, we aim to introduce the MR method to hepatologists and provide a comprehensive overview of the current MR findings that are relevant for hepatologists. Furthermore, we will discuss how to evaluate the quality of MR publications, interpret MR findings, and illustrate good practice of using MR studies in hepatology.

Citations

Citations to this article as recorded by  Crossref logo
  • Childhood Obesity and Age‐Related Diseases: A Systematic Review and Meta‐Analysis of Mendelian Randomization Evidence
    Haoxue Zhu, Xinghao Yi, Mengyu He, Siyi Wu, Ming Li, Shan Gao
    Pediatric Obesity.2026;[Epub]     CrossRef
  • Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supporting in vitro experiments
    Xiaojie Hao, Jingjun Mu
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis
    Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Clinical and Molecular Hepatology.2026; 32(1): 339.     CrossRef
  • Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis
    Yinling Li, Huanhuan Xie, Zhenjie Zhuang, Xin Fang, Wenjun Yang, Yan Luo, Jiangyi Hu, Wei Wang, Haitao Wang, Xiaobing Dou, Junping Shi, Jin Yang
    European Journal of Pharmacology.2026; 1020: 178775.     CrossRef
  • Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD
    Yuanping Shi, Qi Huang, Yingning Liu, Xinlei Zhang, Feng Liu, Huiying Rao, Xueyao Han, Linong Ji, Xiantong Zou
    Diabetes, Obesity and Metabolism.2026; 28(5): 4303.     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver‐Related Outcomes in Multicohorts
    Zhiyu Wu, Shanshan Wu, Shuyao Song, Yating Huang, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Yiping Chen, Huaidong Du, Robin Walters, Iona Millwood, Hao Xu, Xiaoming Yang, Junshi Chen, Seung Up Kim, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochat
    Aging Cell.2026;[Epub]     CrossRef
  • Correspondence to editorial 2 on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis”
    Hyunjae Shin, Moon Haeng Hur, Yoon Jun Kim
    Clinical and Molecular Hepatology.2026; 32(3): e381.     CrossRef
  • Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study
    Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang, Chenxi Li, Shiu Lun Au Yeung
    Diabetes, Obesity and Metabolism.2026; 28(11): 10428.     CrossRef
  • Genetically predicted triglyceride levels and endometriosis risk: Mendelian randomization with exploratory multi-omics analyses
    Yonghong Li, Jianan He, Yuanqing Zhang, Min Yang, Zhimao Jia, Yidan Fan, Shuyun Liu, Mengsha Qi, Lanlan Chen
    PLOS One.2026; 21(8): e0356100.     CrossRef
  • Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation
    Ziyang Qin, Dulguun Juramt, Yuguo Chen, Yunyi Li, Jiaqi Wei, Hongyu Yang, Lanlan Chen, Wei Qiu
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Helicobacter pylori, peptic ulcer disease, and colorectal cancer: a prospective study with genome-wide interaction analysis and Mendelian randomization
    Ziqi Wan, Jiarui Mi, Xiaoyin Bai, Dong Wu, Sunny Hei Wong
    Infectious Agents and Cancer.2025;[Epub]     CrossRef
  • Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study
    Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
    European Journal of Pharmacology.2025; 1005: 178088.     CrossRef
  • Integrative genome-wide analysis unveils the genetic landscape of gallstone disease and highlights novel loci with therapeutic potential
    Haotian Chen, Zhengye Liu, Hanze Du, Mixue Zheng, Ziqi Wan, Nan Zhao, Guanqiao Li, Xiaoyin Bai, Dong Wu, Jiarui Mi
    BMJ Open Gastroenterology.2025; 12(1): e001976.     CrossRef
  • 9,495 View
  • 279 Download
  • 14 Web of Science
  • Crossref
Update in the treatment of cirrhotic patients with portal vein thrombosis
Jialin Wu, Xinyi Deng, Junyang Luo, Zaibo Jiang, Fuda Xie, Bonan Chen, Hoi Wing Leung, Ge Zhang, Ka Fai To, Wei Kang
Clin Mol Hepatol 2025;31(4):1139-1166.
Published online June 24, 2025
DOI: https://doi.org/10.3350/cmh.2025.0411
Portal vein thrombosis (PVT) is characterized by the formation of a thrombus (blood clot) within the portal vein system, including main portal vein and its intrahepatic portal vein branches, and may extend to the superior mesenteric vein or splenic vein. The emergence of PVT is linked to diverse risk factors, encompassing liver conditions with cirrhosis, abdominal infections, previous abdominal surgeries, malignancies, inherited or acquired thrombophilias, and systemic hypercoagulable conditions. Recent studies revealed a possible connection between the occurrence of PVT and either contracting corona virus disease 2019 (COVID-19) or receiving a COVID-19 vaccination. Current treatment strategies were primarily based on symptom management, extent, and progression of thrombosis, but their efficacy was inconsistent and suboptimal. Untimely or inadequate treatment can lead to the progression of the thrombus and increase the risk of complications, such as portal hypertension, variceal bleeding, and hepatic decompensation, posing a significant risk to the patient’s life. Thus, early and appropriate initiation of pharmacologic and interventional treatments, as well as more aggressive strategies, is crucial for the management and prevention of PVT progression and recurrence. This review focuses on the literature on the recent advancements in the treatment of PVT using various therapeutic modalities, including anticoagulant therapy, thrombolysis, thrombectomy, interventional therapy and liver transplant in cirrhotic patients. In addition, we discuss pearls and pitfalls of these strategies for PVT, highlighting recent progress, identifying knowledge gaps, and proposing avenues towards precision management.

Citations

Citations to this article as recorded by  Crossref logo
  • Gastrointestinal bleeding risk in cirrhotic portal vein thrombosis: focus on thrombus extension to superior mesenteric vein
    Sa Lv, Hui Feng, Tianjiao Xu, Hua Tian, Haibo Wang, Dongze Li, Shaoli You, Bing Zhu
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
    Yinghan Chen, Caiyun Lu, Yucheng Xu, Zhidong Zang
    Alimentary Pharmacology & Therapeutics.2026; 64(5): 701.     CrossRef
  • Risk factors and predictive model for transjugular intrahepatic portosystemic shunt dysfunction in cirrhotic patients
    Yongbing Zhao, Tingwei Xiong, Sijie Hu, Hao Zhou, En Liu, Zhengguo Xu, Rui Xie
    European Journal of Gastroenterology & Hepatology.2026; 38(8): 977.     CrossRef
  • Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023
    Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang
    Hepatology International.2026;[Epub]     CrossRef
  • Mechanical Thrombectomy and Shunt Embolization to Manage Gastric Variceal Bleeding with Acute Portal Vein Thrombosis
    Nikhil Shankar, Avinash Bhat Balekuduru, Indushekar Subbanna, Manoj Kumar Sahu
    Gastroenterology, Hepatology and Endoscopy Practice.2026; 6(3): 101.     CrossRef
  • Prevention and treatment of portal vein thrombosis in cirrhosis
    Ke-Ke Jin, Hui-Guo Ding
    World Chinese Journal of Digestology.2026; 34(9): 675.     CrossRef
  • Acute portal vein thrombosis in an elderly man with homozygous mutations of plasminogen activator inhibitor-1 and methylenetetrahydrofolate reductase genes
    Junxiu Chen, Haonan Zhao, Shengye Yang, Huiyuan Lu, Xingshun Qi
    Archives of Medical Science.2025;[Epub]     CrossRef
  • Prediction of bowel resection due to bowel necrosis in recent portal vein thrombosis based on CT presentations and clinical data
    Junyang Luo, Junwei Chen, Hua Tang, Jialin Wu, Xiaohong Wang, Zaibo Jiang, Jie Qin
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Long-term patency of the transjugular intrahepatic portosystemic shunt for portal and superior mesenteric vein thrombosis
    Junyang Luo, Churen Zhou, Yanyang Zhang, Haofan Wang, Caiyun Lu, Jialin Wu, Jie Qin, Zaibo Jiang, Junwei Chen
    Thrombosis Journal.2025;[Epub]     CrossRef
  • 8,324 View
  • 387 Download
  • 6 Web of Science
  • Crossref
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
Clin Mol Hepatol 2025;31(4):1167-1196.
Published online August 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0337
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. The prevalence of MASLD and metabolic dysfunction-associated steatohepatitis (MASH) continues to increase, mirroring the rise in global prevalence of related comorbidities such as obesity and type 2 diabetes mellitus. Due to the alarming rise of these comorbidities, a greater proportion of the population is at risk for developing MASLD and MASH. As such, there has been a significant effort to develop effective therapies for MASLD and MASH. Recently, the U.S. Food and Drug Administration approved resmetirom, a selective thyroid hormone receptor-beta agonist, as the first treatment for patients with MASH. In India, the Drug Controller General of India approved saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, for the treatment of MASLD. Currently, we have various drug classes, including liver-specific therapies, in Phase 3 development with even more agents earlier in the pipeline. This review will discuss prospective therapies in later stages of development such as thyroid hormone receptor-beta agonists, PPAR agonists, glucagon-like peptide-1 receptor agonists, fibroblast growth factor 21 agonists, and fatty acid synthase inhibitors.

Citations

Citations to this article as recorded by  Crossref logo
  • Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
    Xiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, Giovanni Targher, Mark D Muthiah, Daniel Q Huang, Qin-Fen Chen, Mazen Noureddin, Wenhao Li, Vlad Ratziu, Rohit Loomba, Sven M Francque, Arun J Sanyal, Ming-Hua Zheng
    Gut.2026; 75(4): 815.     CrossRef
  • Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend
    Peng-Yao Lin, Jia-Rong Xie, Tian-Chen Qian, Shi-Song Wang, Si-Yi Yu, Wen-Bo Shi, Ying Wang, Lu-Ze Cen, Qing-Jing Zhu, Yi-Yang Zheng, Hui Gao, Rong Fang, Zhao-Xia Xia, Ai-Ming Liu, Lei Xu
    International Journal of Molecular Medicine.2026; 57(4): 1.     CrossRef
  • Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study”
    Xingyu Yao
    Clinical and Molecular Hepatology.2026; 32(2): e267.     CrossRef
  • Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
    Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2026; 17(7): e01042.     CrossRef
  • An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease
    Jinguo Wang, Ying Zhang, Shuo Sun, Lanyan Hu, Dong Yang
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • The dynamic spectrum of steatotic liver disease: the global perspective
    Zobair M. Younossi, Shira Zelber-Sagi, Markos Kalligeros, Dana Ivancovsky Wajcman, Linda Henry, Laura Sol Grinshpan, Mads Israelsen, Luis Antonio Diaz, Jiangao Fan, Marco Arrese, Ajay Duseja, C. Wendy Spearman, Mohamed El-Kassas, Yusuf Yilmaz, Juan Pablo
    Nature Reviews Gastroenterology & Hepatology.2026; 23(11): 812.     CrossRef
  • LAD-NASH score using multiparametric ultrasound for identification of at-risk MASH: head-to-head comparison with the FAST score
    Seung-seob Kim, Jae Seung Lee, Min Young Lee, Sunyoung Lee
    Ultrasonography.2026; 45(5): 439.     CrossRef
  • Lipopolymer Nanoparticle‐Mediated In Vivo CRISPR‐Cas9 Editing of Mrg15 Restores Mitochondrial Mitophagy to Alleviate Metabolic‐Associated Steatohepatitis
    Zixi Zhang, Jing Liao, Tingfeng Yu, Sijie Chen, Ling Zeng, Guanzi Chen, Qian Shen, Yingsen Tang, Meng Jiang, Jinjin Chen, Lingyun Wang
    Advanced Healthcare Materials.2026;[Epub]     CrossRef
  • Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS
    Jia‐Xin Yin, Yan‐Lai Zhang, Qun Liu, Rui Liu, Hai‐Yang Yuan, Sui‐Dan Chen, Ming‐Hua Zheng, Kai Wang, Ni Tang, Ai‐Long Huang
    Advanced Science.2026;[Epub]     CrossRef
  • Multidimensional regulation of hepatic macrophages in chronic liver disease: from metabolic reprogramming to intercellular and interorgan crosstalk
    Che Xu, Xin-Yu Zhu, Hai-Na Xie, Jing An, Jun-Feng Zhu, Si-Cheng Gao
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Mapping nanodelivery design for liver fibrosis: A mechanism-informed framework for functional integration
    Hyunjun Moon, Haeju Park, Chan Hyeok Lee, Hyun Jin Kim, Juntaek Oh, Jeong Uk Choi, Jin Hee Na, Sangmin Lee
    Advanced Drug Delivery Reviews.2026; : 115987.     CrossRef
  • 10,751 View
  • 275 Download
  • 10 Web of Science
  • Crossref
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clin Mol Hepatol 2025;31(4):1197-1212.
Published online July 28, 2025
DOI: https://doi.org/10.3350/cmh.2025.0492
Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Natural dehydrocostus lactone-based analogues as new structural PDPK1 allosteric activators against HBV
    Hang Sun, Yu-Jing Mao, Dan-Yang Zhu, Rui-Xian Xu, Bi-Cheng Zhang, Ying Sang, Yi-Zhi Liu, Yang Feng, Guotai Yang, Hao Chen, Shao-Xing Dai, Min Xu
    European Journal of Medicinal Chemistry.2027; 321: 119455.     CrossRef
  • Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
    Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
    Current Microbiology.2026;[Epub]     CrossRef
  • Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
    Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao
    Hepatology Communications.2026;[Epub]     CrossRef
  • Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications
    Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou
    Portal Hypertension & Cirrhosis.2026; 5(1): 65.     CrossRef
  • Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
    Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
    Bioorganic & Medicinal Chemistry.2026; 138: 118662.     CrossRef
  • Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
    Kui Wang, Ruchen Zhou
    Clinical and Molecular Hepatology.2026; 32(2): e211.     CrossRef
  • Zinc finger protein ZBTB7A suppresses hepatitis B virus replication by attenuating FXRα-mediated HBV transcription and lowering covalently closed circular DNA levels
    Dan Xu, Zhenyu Zhao, Beinu Guo, Zhen Wei, Chen Li, Sichen Luo, Wen Shu, Zhongliang Shen, Mengji Lu, Jiming Zhang, Hecun Zou, Fahong Li, Yong Lin
    Antiviral Research.2026; 252: 106469.     CrossRef
  • Hepatitis B Research in Peru, 1988–2023: Geographic Inequities, Thematic Gaps, and Misalignment with Disease Burden
    Jhon Omar Palomino-Tenorio, Obert Marín-Sánchez, Jimmy Ango-Bedriñana, Ruy D. Chacón, Homero Ango-Aguilar
    Pathogens.2026; 15(7): 708.     CrossRef
  • Supramolecular Self-Assembly of Lycorine with Glycyrrhizic Acid into a Nanodrug for Safe and Sustained Anti-HBV Therapy
    Hang Sun, Zi-Dong He, Bei-Bei Jia, Bo Yuan, Ling-Chuan Kong, Rui-Xian Xu, Qiong Wang, Wen-Jing Pan, Hao Chen, Shao-Xing Dai, Min Xu
    ACS Applied Bio Materials.2026; 9(15): 7143.     CrossRef
  • Dual HBV cccDNA-linked HiBiT reporter hepatocyte models for screening of candidate cccDNA modulators
    Jiali Cao, Yali Zhang, Jian Ma, Shaojuan Wang, Yangtao Wu, Hualong Xiong, Mingfeng Wang, Tianshu Shi, Baorong Fu, Xiaochun Fu, Xiaoli Chen, Huiming Ye, Ningshao Xia, Quan Yuan
    Virulence.2026;[Epub]     CrossRef
  • Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk
    Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim
    Journal of Gastroenterology and Hepatology.2026; 41(10): 3199.     CrossRef
  • Decoding sequence recognition code of nucleic acid‐binding proteins of human‐infecting DNA viruses
    Meifang Tang, Shifei Yang, Haiqian Ma, Ruoying Guo, Jie Chen, Hui Zhang, Jinghan Zhang, Wei Sun, Yun Wei, Ligang Fan, Jian Yan
    iMeta.2026;[Epub]     CrossRef
  • Renal Safety and Antiviral Effectiveness of Tenofovir Alafenamide Versus Entecavir in Patients With Chronic Hepatitis B and Chronic Kidney Disease: A Real‐World Cohort Study
    Danfeng Ren, Xiangyun Dang, Shan Fu, Ze Zhang, Tianzhi Ni, Wentao Zhang, Yingren Zhao, Jinfeng Liu
    Journal of Viral Hepatitis.2026;[Epub]     CrossRef
  • ANTIVIRAL THERAPIES AND PUBLIC HEALTH SURVEILLANCE IN THE TREATMENT OF CHRONIC VIRAL HEPATITIS
    Tarcila de Brito Lira Dal Monte Gadelha, Bruno Machado Aarão, Fernando Falavigna, Sanderson Breno Palheta Corrêa, Rosangela Maria Pereira Valoes Carvalho, Stefany Nazario dos Santos, Erica Cristina Carvalho, Alexandre Leonel Júnior, Dayane de Castro Lopes
    International Journal of Health Management Review.2026; 12(3): e691.     CrossRef
  • Reply to JFMA-D-26-02276
    Chih-Lin Lin, Jia-Horng Kao
    Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
  • Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
    Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
  • 11,055 View
  • 326 Download
  • 14 Web of Science
  • Crossref
Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma
I-Cheng Lee, Hung-Wei Wang, Wei Teng, Tsung-Jung Lin, Chien-Hung Chen, Hsueh-Chou Lai, Teng-Yu Lee, Ching-Wei Chang, Chao-Hung Hung, Chia-Yen Dai, Yi-Ping Hung, Ying-Chun Shen, Chien-Wei Su, Ming-Chih Ho, Wei-Chen Lee, Gar-Yang Chau, Chin-Tsung Ting, Po-Chin Liang, Chien-An Liu, Pi-Yi Chang, Kuan-Yang Chen, Shi-Ming Lin, Li-Tzong Chen, Yi-Hsiang Huang, TLCA Intermediate Stage HCC Working Group
Clin Mol Hepatol 2025;31(4):1213-1232.
Published online August 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0724
Intermediate-stage hepatocellular carcinoma (HCC) encompasses a diverse patient population that requires individualized treatment strategies and a multidisciplinary approach. Recent advancements in systemic therapy have expanded the therapeutic options for intermediate-stage HCC, allowing for combination strategies such as systemic therapy with transarterial chemoembolization (TACE) and upfront systemic therapy for individuals deemed unsuitable for TACE. Additionally, the ongoing development of treatment modalities for intermediate-stage HCC has improved the potential for curative conversion and tumor downstaging. Nevertheless, consensus on the optimal management of intermediate-stage HCC remains limited. Thus, the primary aim of this study was to develop a set of consensus guidelines for the management of intermediate-stage HCC. To address this gap, the Taiwan Liver Cancer Association (TLCA) established a working group to develop a multidisciplinary strategy for managing intermediate-stage HCC. Here, we present eight consensus statements formulated by this expert panel, which outline criteria for TACE unsuitability, treatment recommendations based on TACE eligibility, and considerations for various modalities, including conventional TACE, drug-eluting bead TACE, and transarterial radioembolization, as well as the appropriate timing for initiating systemic therapy to enable curative conversion and downstaging. These statements provide specific, evidence-based recommendations for clinicians, addressing treatment pathways based on TACE eligibility and other key considerations for intermediate-stage HCC management. The development of this consensus guideline is intended to aid clinicians in selecting the most appropriate treatment pathway for intermediate-stage HCC, support personalized treatment planning, and ultimately enhance the feasibility of achieving curative conversion.

Citations

Citations to this article as recorded by  Crossref logo
  • Editorial: Tumour Burden Score and Extrahepatic Progression After TACE—Refining Risk Stratification Beyond the Liver
    Chien‐Wei Su
    Alimentary Pharmacology & Therapeutics.2026; 63(9): 1316.     CrossRef
  • Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy
    Chen-Ta Chi, Yi-Hsiang Huang
    Journal of Gastroenterology.2026; 61(8): 1041.     CrossRef
  • Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab
    Junichi Shindoh, Yusuke Kawamura, Tetsuya Hosaka, Takuma Okada, Satoshi Okubo, Masaru Matsumura, Norio Akuta
    Annals of Surgical Oncology.2026; 33(10): 8799.     CrossRef
  • Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe
    David J. Pinato, Eleonora Alimenti, Pasquale Lombardi, Juan Vaz, Antonia Digklia, Julien Edeline, Najib Ben Khaled, Emanuela Di Giacomo, Bernhard Scheiner, Jose Presa Ramos, Grainne M. O’Kane, Sarah Cappuyns, Giulia Tesini, Lorenza Rimassa
    The Lancet Regional Health - Europe.2026; 70: 101839.     CrossRef
  • Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis
    Jongin Lee, Kwon Yong Tak, Hee Sun Cho, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Ji Won Han
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Goal-directed minimally invasive treatment of hepatocellular carcinoma across the disease course: a scenario-based clinical framework
    Rui Cao, Xiao You, Yuhan Huang, Yu Zhang, Feng Xia, Qi Cheng
    Mini-invasive Surgery.2026;[Epub]     CrossRef
  • Preoperative radioembolization versus chemoembolization and upfront resection for resectable hepatocellular carcinoma beyond the Milan criteria
    Jeayeon Park, Gyung Sun Lim, Yunmi Ko, Hyunjae Shin, Moon Haeng Hur, Su Young Hong, Suk Kyun Hong, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, YoungRok Choi, Su Jong Yu, Hyo-Cheol Kim, Kwang-Woong Lee, Jung-Hwan Yoon, Kyung-Suk Suh, Jin Wook Chung, Yoon Jun
    European Radiology.2026;[Epub]     CrossRef
  • Advances in assessment systems and non-pharmacological intervention strategies for cancer-related fatigue following transarterial chemoembolization in hepatocellular carcinoma: a narrative review
    Shiying Yang, Xuelei Yao, Yali Ren, Teng Ding, Jiamin Gao, Lin Shentu
    Supportive Care in Cancer.2026;[Epub]     CrossRef
  • Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma
    Chi-Ping Tan, Teng-Yu Lee, I-Cheng Lee, Kuo-Cheng Wu, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Chen-Ta Chi, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
    Liver Cancer.2025; : 1.     CrossRef
  • 11,220 View
  • 538 Download
  • 14 Web of Science
  • Crossref

Original Articles

Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure
Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash Magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
Clin Mol Hepatol 2025;31(4):1233-1251.
Published online December 13, 2024
DOI: https://doi.org/10.3350/cmh.2024.0554
Background/Aims
Acute liver failure (ALF) has high mortality predominantly due to compromised immune system and increased vulnerability to bacterial and fungal infections.
Methods
Plasma lipidome and fungal peptide-based community (mycobiome) analysis were performed in discovery cohort (ALF=40, healthy=5) and validated in a validation cohort of 230 patients with ALF using high-resolution-mass-spectrometry, artificial neural network (ANN) and machine learning (ML).
Results
Untargeted lipidomics identified 2,013 lipids across 8 lipid group. 5 lipid-species—phosphatidylcholine (PC)[15:0/17:0], PC[20:1/14:1], PC[26:4/10:0], PC[32:0] and TG[4:0/10:0/23:6]—significantly differentiated ALF-NS (FC>10, P<0.05, FDR<0.01). Mycobiome alpha/beta diversity was significantly higher and showed 4 phyla and >20 species significantly dysregulated in ALF-NS linked with lipid metabolism, fatty acid elongation in ER, and others (P<0.05). Lipid and mycobiome diversity values in ALF-NS were strongly correlated (r2>0.7, P<0.05). Multi-modular correlation network showed striking associations between lipid, fungal peptide modules, and clinical parameters specific to ALF-NS (P<0.05). Cryptococcus amylolentus CBS6039 and Penicillium oxalicum 1142 directly correlated with phosphatidylcholine, triglycerides, and severity in ALF-NS (r2>0.85, P<0.05). POD-fungus and POD-lipids showed direct association with infection, necrosis, and hepatic encephalopathy (Beta>1.2, P<0.05). POD-lipid (AUC=0.969 and HR=1.99 [1.02–2.04]) superseded POD-fungus and severity indices for early-mortality prediction. Finally, significant increase in PC (15:0/17:0) level showed highest normalized importance, and ANNs and ML predicted early mortality with >95% accuracy, sensitivity, and specificity. Interestingly, fungal surveillance protein Clec7a was significantly downregulated (>2-fold), leading to a notable increase in fungal infection-mediated choline/phosphatidylcholine and associated enzymes (FC>1.5; Kennedy cycle). This contributed to phosphatidic acid-mediated hyper-inflammation in ALF-NS.
Conclusions
In ALF, the plasma lipidome and mycobiome are dysregulated. Increased circulating phosphatidylcholine could stratify ALF predisposed to early mortality or require emergency liver transplantation.

Citations

Citations to this article as recorded by  Crossref logo
  • Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
    S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas
    Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 411.     CrossRef
  • Plasma lipidomic and fungal signatures predict early mortality in acute liver failure
    Yu Ji Kim, Jong-Won Kim
    Clinical and Molecular Hepatology.2026; 32(1): e21.     CrossRef
  • Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia
    Emily J. Mason, Jeremy M. Schraw, John P. Woodhouse, M. Monica Gramatges, Kevin J. Williams, Baojiang Chen, Melissa B. Harrell, Olga A. Taylor, Michael E. Scheurer, Philip J. Lupo, Karen R. Rabin, Joanna S. Yi, Van Huynh, Steven D. Mittelman, Etan Orgel,
    Supportive Care in Cancer.2026;[Epub]     CrossRef
  • The signatures and crosstalk of gut mycobiome, microbiome, and metabolites in drug-induced liver injury
    Weiyan Huang, Yirui Hu, Zexuan Li, Jiake Che, Shuyan Wang, Ye Yang, Shengqi Yan, Yue Chen, Wenkang Gao, Fuyu Yang, Ting Wei, Kai Liu, Yuanqing Zhu, Yupin Tan, Yue Yang, Xinyang Wang, Yonggang Yuan, Zhuang Cao, Xiaotong Du, Jiahao Liu, Ling Yang, Huikuan C
    Mycology.2026;[Epub]     CrossRef
  • Distinct bile mycobiome signature identifies fungal peptide panel predictive for gallbladder carcinoma
    Sanju Yadav, Nupur Sharma, Manisha Yadav, Neha Sharma, Gaurav Tripathi, Sadam H. Bhat, Sushmita Pandey, Babu Mathew, Vasundhra Bindal, Rimsha Saifi, Vipul Sharma, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras
    Molecular Therapy Oncology.2026; 34(2): 201220.     CrossRef
  • Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models: Correspondence to letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatur
    Neha Sharma, Sushmita Pandey, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
    Clinical and Molecular Hepatology.2026; 32(3): e392.     CrossRef
  • Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy
    Luze Cen, Ying Wang, Jie Yang, Wenbo Shi, Pengyao Lin, Weiqi Zhang, Xiaobo Xiang, Xinchang Gao, Jing Huang, Jiongze Fang, Xi Yu, Manyun Dai, Aiming Liu, Caide Lu
    iScience.2026; 29(8): 116962.     CrossRef
  • Methodological considerations for lipidomic and fungal peptide-based risk stratification in acute liver failure: Letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in a
    Hu Fu
    Clinical and Molecular Hepatology.2026; 32(3): e283.     CrossRef
  • Metabolomic profiling of Ashwagandha (Withania somnifera): linking bioactive compounds to functional therapeutic roles
    Gaurav Tripathi, Vasundhra Bindal, Sanju Yadav, Manisha Yadav, Neha Sharma, Sushmita Pandey, Vipul Sharma, Nupur Sharma, Babu Mathew, Yash Magar, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
    Frontiers in Molecular Biosciences.2026;[Epub]     CrossRef
  • 12,557 View
  • 322 Download
  • 9 Web of Science
  • Crossref
Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease
Oveis Jamialahmadi, Endrina Mujica, Lowri Morris, Rosellina Margherita Mancina, Ester Ciociola, Sami F. Qadri, Samantha Maurotti, Francesco Malvestiti, Ruifang Li-Gao, Luisa Ronzoni, Federica Tavaglione, Hannah Maude, Amin Allalou, Anastasia Emmanouilidou, Umberto Vespasiani-Gentilucci, Frits Richard Rosendaal, Hannele Yki-Järvinen, Inês Cebola, Luca Valenti, Marcel den Hoed, Stefano Romeo
Clin Mol Hepatol 2025;31(4):1252-1268.
Published online June 2, 2025
DOI: https://doi.org/10.3350/cmh.2025.0159
Background/Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) may progress to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. So far, genome-wide association studies explain a small fraction of MASLD heritability.
Methods
We sought to identify novel genetic determinants of MASLD by exploring interactions between genetic variants and body mass index (BMI). First, we examined genome-wide interactions with BMI for circulating alanine aminotransferase (ALT) levels using UK Biobank data. For identified loci, we next examined associations with hepatic proton density fat fraction (PDFF) in 35,146 independent UK Biobank participants. Associations with PDFF were replicated in four independent European cohorts, followed by a phenome-wide association study. Finally, we used human liver epigenomic maps and CRISPR/Cas9 experiments in vitro and in vivo to functionally characterize the CYP7A1 locus.
Results
Thirteen loci interact with BMI for ALT (P<5E-8), including eight well-known genetic modulators of MASLD. Two loci—UBXN2B/CYP7A1 and GIPR—are additionally associated with PDFF. For the intronic rs34783010 in GIPR, the minor T allele is associated with lower BMI and higher HbA1c and liver triglyceride content in humans. The UBXN2B/CYP7A1 locus is associated with PDFF in four additional European cohorts. Epigenomic data and in vitro experiments in human liver cells prioritise rs10504255 and CYP7A1 as the functional effectors in this locus. Perturbation of CYP7A1 orthologues using CRISPR/Cas9 results in less liver fat in 10-day-old, metabolically challenged zebrafish larvae.
Conclusions
A genome-wide single nucleotide polymorphism×BMI design fuelled identification of two MASLD genes: CYP7A1 and GIPR.

Citations

Citations to this article as recorded by  Crossref logo
  • Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis
    Eric Trépo, Jessica Zucman-Rossi, Jean-Charles Nault
    Nature Reviews Gastroenterology & Hepatology.2026; 23(6): 493.     CrossRef
  • Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
    Julia Kozlitina, Stefano Romeo, Helen H. Hobbs
    Hepatology.2026;[Epub]     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation
    Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan
    Clinica Chimica Acta.2026; 589: 121028.     CrossRef
  • Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology
    Carlos José Pirola, Silvia Sookoian
    Med.2026; 7(6): 101131.     CrossRef
  • Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
    Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2026; 17(7): e01042.     CrossRef
  • Molecular Mechanisms Associated with Metabolic Dysfunction: Contributions of Nutritional Genomics
    Natália Ellen Delmicon, Nathália dos Reis Franco, Giovanna Cavanha Corsi, Roberta Mi Kyong Kim Cho, Helen Cristina Vidal, Marcelo Macedo Rogero
    Metabolites.2026; 16(7): 501.     CrossRef
  • Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum
    Han Ah Lee, Gi-Ae Kim, Won Kim
    Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0367.     CrossRef
  • Genome-wide analyses identify 60 loci associated with liver triglyceride content
    Oveis Jamialahmadi, Shahir Mowlaei, Kyla Z. Gelev, Rosellina M. Mancina, Valentina Flagiello, Julia Kozlitina, Päivi Pajukanta, Luca Valenti, Stefano Romeo
    Nature Genetics.2026; 58(11): 2772.     CrossRef
  • GLP1R and GIPR gene sequencing for glycemic response to DPP-4 inhibitors in T2DM patients
    Kübra Çiğdem Pekkoç Uyanık, Zeynep Gizem Todurga Seven, Hülya Irmak Aksan, Erhan Raşit Agay, Sibel Özyazgan
    Frontiers in Life Sciences and Related Technologies.2026; 7: 140.     CrossRef
  • Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
    Rosellina M. Mancina, Luca Valenti, Stefano Romeo
    Nature Metabolism.2025; 7(11): 2199.     CrossRef
  • 9,079 View
  • 318 Download
  • 13 Web of Science
  • Crossref
Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy
Moana Witte, Carlos Oltmanns, Jan Tauwaldt, Hagen Schmaus, Jasmin Mischke, Gordon Grabert, Mara Bretthauer, Lennart M. Roesner, Thomas Werfel, Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Tim Kacprowski, Anke R.M. Kraft, Markus Cornberg
Clin Mol Hepatol 2025;31(4):1269-1284.
Published online June 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0292
Background/Aims
Hepatitis C virus (HCV) infection remains a global health challenge, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Despite the high efficacy of direct-acting antiviral therapy in achieving sustained virologic response (SVR), concerns persist regarding long-term immune alterations and residual risks, particularly in cirrhotic patients.
Methods
This study investigates 75 soluble immune mediator (SIM) profiles in 102 chronic HCV patients, stratified by cirrhosis status, at therapy initiation, end of treatment, and long-term follow-up (median 96 weeks). Findings were compared with 51 matched healthy controls and validated in an independent cohort of 47 cirrhotic patients, 17 of whom developed HCC.
Results
We observed significant SIM alterations at baseline, with cirrhotic patients displaying a more profoundly dysregulated inflammatory milieu. Despite an overall decline in inflammatory markers following SVR, persistent alterations were evident, particularly in cirrhotic patients. Notably, those with liver stiffness exceeding 14 kPa exhibited sustained inflammatory dysregulation, correlating with liver elastography values. Key SIM such as interleukin (IL)-6, IL-8, urokinase plasminogen activator, and hepatocellular growth factor remained elevated and were associated with HCC development. Network analysis highlighted their roles in liver fibrosis, regeneration, and carcinogenesis.
Conclusions
These findings underscore the importance of early antiviral intervention to prevent cirrhosis-related sequelae. Future studies should explore the mechanistic pathways linking chronic inflammation, fibrosis, and oncogenesis to identify predictive biomarkers and novel therapeutic targets. Addressing persistent immune alterations post-HCV clearance may improve long-term outcomes, particularly in patients with advanced liver disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Gut microbiota–immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities
    Jihao Yang, Yishuang Dai, Jia Li
    Oncology Reviews.2026;[Epub]     CrossRef
  • Hepatitis C elimination: is it time to redefine the goals?
    Yasser Fouad, Ming-Lung Yu, Saeed Hamid, Robert G. Gish, Mohammed Eslam
    Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 376.     CrossRef
  • Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy”
    So-Young Kim, Eui-Cheol Shin
    Clinical and Molecular Hepatology.2026; 32(2): 935.     CrossRef
  • Isoliensinine targets NPC1 to reprogram lysosomal cholesterol and establish a reversible antiviral state
    Lingdong Kong, Xin Jia, Meiqi Zhang, Yiying Li, Yansong Gao, Haoran Shi, Qiqi Li, Cuiqin Cheng, Zheng Luo, Min Li, Anlong Xu, Yao Wang
    Acta Pharmaceutica Sinica B.2026;[Epub]     CrossRef
  • HBV Dominance Is Associated With a Distinct Inflammatory Milieu in HBV/HCV Coinfection
    Carlos Oltmanns, Moana Witte, Anika Wranke, Katja Deterding, Heiner Wedemeyer, Christine S. Falk, Anke R. M. Kraft, Steffen B. Wiegand, Markus Cornberg
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection
    Sonia Arca-Lafuente, Violeta Lara-Aguilar, Manuel Llamas-Adán, Sergio Grande-García, Andrés Deza de la Casa, Luz Martín-Carbonero, Pablo Ryan, Ignacio de los Santos, Mariano Matarranz, Mª Ángeles Jiménez-Sousa, Amanda Fernández-Rodríguez, Verónica Briz
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • 6,256 View
  • 162 Download
  • 4 Web of Science
  • Crossref
Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
Clin Mol Hepatol 2025;31(4):1285-1297.
Published online June 13, 2025
DOI: https://doi.org/10.3350/cmh.2025.0258
Background/Aims
Hepatocellular carcinoma (HCC) frequently recurs after curative treatment, posing challenges to long-term survival. Although contrast-enhanced multiphasic computed tomography (CECT) is commonly used for detecting recurrence, it is associated with risks such as radiation exposure and contrast agent reactions. This study aimed to compare the diagnostic performance of non-contrast magnetic resonance imaging (NC-MRI) with CECT for detecting recurrent HCC.
Methods
In this prospective multicenter intra-individual head-to-head comparison trial (study identifier: NCT05690451, KCT0006395), participants who had undergone curative treatment for HCC and remained recurrence-free for over two years were enrolled. Each participant underwent three follow-up imaging sessions at 2–6-month intervals using both CECT and NC-MRI. The primary outcome was the detection accuracy of each modality, analyzed using the generalized estimating equation analysis. Secondary outcomes included sensitivity and specificity.
Results
The study included 203 participants with a total of 528 paired imaging sessions, identifying recurrent HCC in 22 cases (10.8%). Among these, 21 cases involved intrahepatic recurrence with a median tumor size of 1.3 cm, and one case had aortocaval lymph node metastasis. NC-MRI achieved a detection accuracy of 96.6% (196/203), higher than CECT’s 91.6% (186/203) (P=0.006). NC-MRI also showed greater sensitivity (77.3% [17/22] vs. 36.4% [8/22]; P=0.012), while specificity was comparable between NC-MRI and CECT (98.9% [179/181] vs. 98.3% [178/181]; P=0.999).
Conclusions
NC-MRI demonstrated higher sensitivity and accuracy compared to CECT in detecting recurrent HCC in patients who had been disease-free for over two years following curative treatment, indicating its potential as a preferred imaging modality for this purpose.

Citations

Citations to this article as recorded by  Crossref logo
  • Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma: A paired validation study
    Laizhu Zhang, Weiwei Zong, Jialin Gao, Huan Li, Leizhou Xia, Xiaoli Mai, Jun Chen, Binghua Li, Decai Yu
    Clinical and Molecular Hepatology.2026; 32(1): e34.     CrossRef
  • Updates in Abbreviated MRI‐Based HCC Surveillance
    Hyo Jung Park, So Yeon Kim, Young‐Suk Lim
    Journal of Gastroenterology and Hepatology.2026; 41(3): 914.     CrossRef
  • Moving beyond Ultrasound for Hepatocellular Carcinoma Surveillance in High-Risk Patients with Chronic Hepatitis B
    Hae Lim Lee
    Gut and Liver.2026; 20(2): 174.     CrossRef
  • Correspondence to editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography”
    Dong Ho Lee
    Clinical and Molecular Hepatology.2026; 32(2): e221.     CrossRef
  • Correspondence to letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography”
    Dong Ho Lee
    Clinical and Molecular Hepatology.2026; 32(2): e251.     CrossRef
  • Beyond diagnostic accuracy: Economic and clinical considerations for NC-MRI in late HCC recurrence surveillance: Letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treat
    Qi-Feng Chen, Sui-Xing Zhong, Ming Zhao
    Clinical and Molecular Hepatology.2026; 32(2): e175.     CrossRef
  • Interreader Agreement for Individual Ancillary Features in LI-RADS CT/MRI Version 2018: A Systematic Review and Meta-Analysis
    Yong Jun Jung, Sang Hyun Choi, Subin Heo, Dong Hwan Kim, Suk Kim, Seung Baek Hong
    American Journal of Roentgenology.2026;[Epub]     CrossRef
  • HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to
    Hyungjin Rhee, Jin-Young Choi
    Clinical and Molecular Hepatology.2026; 32(2): 939.     CrossRef
  • Revisiting the role of non-contrast MRI in recurrent HCC: Bridging diagnostic performance and real-world applicability: Letter to the editor on “Non-contrast MRI for detection of late recurrent hepatocellular carcinoma after curative treatment: A prospect
    Lu Sun, Xin Zhang
    Clinical and Molecular Hepatology.2026; 32(2): e172.     CrossRef
  • Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
    Hyo Jung Park, Dong Ho Lee, Won Chang, Hae Young Kim, Dong Hwan Kim, Won-Mook Choi, Sung Won Chung, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Han Chu Lee, Young-Suk Lim, Seon-Ok Kim, Amit G Singal, So Yeon Kim
    BMJ Open.2026; 16(4): e116809.     CrossRef
  • The Use of Non‐Contrast Abbreviated MRI for the Detection of Recurrent Hepatocellular Carcinoma in Postoperative Surveillance
    Jianwei Chen, Yuemin Zhu, Dechun Zheng, Liting Wen, Juyi Wu, Qiuyuan Yue, Zhuting Fang
    Journal of Magnetic Resonance Imaging.2026; 64(3): 722.     CrossRef
  • Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis
    Mohammad Jarrah, Mohammed Al-Hasan, Mariadelcarmen Yanez, Maria V. Yow, Eunice Amador, Diya Kar, Fouzia Ahmed, Nicole E. Rich, Sneha Deodhar, Jenna Bedrava, Claire Chen, Amit G. Singal
    Cancers.2026; 18(16): 2711.     CrossRef
  • Visualization quality and effectiveness of noncontrast-abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhotic patients with ultrasound visualization score C
    Hyun Kyung Yang, Sunyoung Lee, Min Young Lee, Boryeong Jeong, Eunju Kim, Jeong Hee Yoon
    European Radiology.2026;[Epub]     CrossRef
  • Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis
    Mohammad Jarrah, Sneha Deodhar, Lisa Quirk, Mohammed Al-Hasan, Ashish Sharma, Guruveer Bhamra, Julia Terrell, Fasiha Kanwal, Yujin Hoshida, Nicole E. Rich, Purva Gopal, Amit G. Singal
    Cancers.2025; 17(23): 3835.     CrossRef
  • 11,663 View
  • 246 Download
  • 17 Web of Science
  • Crossref
Factors associated with hepatitis B mother-to-child transmission in a national prevention program
Moran Ki, Byung-Woo Kim, Dahye Baik, Jong-Hyun Kim
Clin Mol Hepatol 2025;31(4):1298-1315.
Published online June 24, 2025
DOI: https://doi.org/10.3350/cmh.2025.0214
Background/Aims
Hepatitis B virus (HBV) mother-to-child transmission (MTCT) remains a global health concern, with over 90% of perinatal infections leading to chronic HBV. To evaluate long-term trends in MTCT rates and associated factors within Korea’s national program.
Methods
Population-based cohort study using linked data from the Perinatal Hepatitis B Prevention Program (PHBPP) and National Health Insurance Service in Korea. The study included HBsAg-positive mother-infant pairs with post-vaccination serologic results from 2002 to 2021.
Results
Among the 154,478 mother-infant pairs, the overall MTCT rate after prophylaxis was 2.3%. Antiviral use lowered MTCT rates (0.9% vs. 2.4%) particularly in HBeAg-positivity (1.0% vs. 5.9%; adjusted odds ratio [aOR] 0.21; 95% confidence interval [CI] 0.14–0.32). Lower MTCT rates were observed for cesarean section vs. vaginal delivery (1.9% vs. 2.6%; aOR 0.78; 95% CI 0.73–0.84) and breastfeeding vs. formula feeding (1.8% vs. 2.8%; aOR 0.65; 95% CI 0.56–0.76). Annual MTCT rates decreased from 3.6% (2002–2005) to 1.3% (2018–2021). Antivirals reduced MTCT rates; initiation at 14–27 weeks (0.39%), or 28–32 weeks (0.44%) vs. ≥33 weeks (1.47%); postpartum continuation (0.55%) vs. antepartum discontinuation (1.44%); use ≥61 days (0.51%) vs. 1–60 days (1.67%). Lower MTCT risk was associated with maternal (old age, high income) and infant (female sex, preterm birth) factors.
Conclusions
This comprehensive analysis of the PHBPP in Korea demonstrates that the use of antivirals, breastfeeding, and cesarean section, combined with conventional immunoprophylaxis, has significantly reduced MTCT rates. These results are crucial for global HBV elimination and can help to guide HBV MTCT prevention strategies.

Citations

Citations to this article as recorded by  Crossref logo
  • Redefining MTCT prevention strategies toward HBV elimination: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”
    Eunho Choi, Ji Hoon Kim, Young-Sun Lee
    Clinical and Molecular Hepatology.2026; 32(2): 943.     CrossRef
  • Redefining MTCT prevention strategies toward HBV elimination: Correspondence to editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”
    Moran Ki, Jong-Hyun Kim
    Clinical and Molecular Hepatology.2026; 32(2): e224.     CrossRef
  • Breaking the chain of perinatal hepatitis B transmission: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”
    Shang-Chin Huang, Jia-Horng Kao
    Clinical and Molecular Hepatology.2026; 32(2): 946.     CrossRef
  • Reply to correspondence on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”
    Eunho Choi, Ji Hoon Kim, Young-Sun Lee
    Clinical and Molecular Hepatology.2026; 32(2): e262.     CrossRef
  • Factors influencing breastfeeding failure in mothers with hepatitis B infection: a qualitative study
    Xin Jiang, Hui Jiang, Rong Huang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Implementation gaps and policy priorities for viral hepatitis elimination in India
    Trina Sengupta, Saurav Basu
    Discover Public Health.2026;[Epub]     CrossRef
  • Predictors of seronegativity to HBV vaccine in infants of HBsAg-positive mothers in a national prevention program
    Moran Ki, Byung-Woo Kim, Naradi Baduge, Jong-Hyun Kim
    JHEP Reports.2026; : 102032.     CrossRef
  • 7,260 View
  • 187 Download
  • 7 Web of Science
  • Crossref
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen
Clin Mol Hepatol 2025;31(4):1316-1332.
Published online July 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0332
Background/Aims
The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods
Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results
HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions
In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Zhujun Cao, Richard Moreau
    Clinical and Molecular Hepatology.2026; 32(2): 953.     CrossRef
  • Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Changze Hong, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(2): e227.     CrossRef
  • Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
    Norihiro Imai
    Clinical and Molecular Hepatology.2026; 32(2): 949.     CrossRef
  • Gestational and Congenital Toxoplasmosis: An Updated Review with Emphasis on High-Prevalence Countries
    Alan Roberto Hatanaka, Antonio Braga, Evelyn Traina, Larissa Keren de Azevedo Teixeira, Carolina Longo, Pedro Teixeira Castro, Heron Werner, Gustavo Yano Callado, Edward Araujo Júnior
    Women.2026; 6(3): 43.     CrossRef
  • 6,797 View
  • 168 Download
  • 6 Web of Science
  • Crossref
Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Yuli Lin, Wulei Hou, Mengxiao Ge, Zhihao Wu, Linlin Huang, Haoye Liu, Wenli Zhang, Xiyu Deng, Lanxin Wang, Ming Guan, Chunhua Song, Zuoyun Wang, Dongqin Yang
Clin Mol Hepatol 2025;31(4):1333-1354.
Published online August 8, 2025
DOI: https://doi.org/10.3350/cmh.2024.1041
Background/Aims
Excessive lipid accumulation in hepatocytes is a critical cause of metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Ankyrin repeat and SOCS box protein 3 (ASB3) is an E3 ubiquitin ligase that mediates diverse disease processes; however, the direct substrates of ASB3 in lipid metabolism and its role in MASLD remain unexplored.
Methods
We generated ASB3 knockout mice fed a high-fat diet to induce MASLD. Oxygen consumption and fatty acid oxidation (FAO) were used to assess lipid metabolism. LC-MS/MS and IP were used to verify the ASB3 target protein. Correlation analysis was conducted on the cohort of MASLD patients vs. the control group.
Results
Loss of the ASB3 E3 ubiquitin ligase in hepatocytes strengthens mitochondrial FAO, thereby influencing energy consumption to decrease triglyceride storage and lipid accumulation. Quantitative lysine ubiquitination proteomics revealed that ASB3 directly mediated the ubiquitin levels at two sites (K180 and K639) in carnitine palmitoyl transferase 1A (CPT1A), a rate-limiting enzyme of FAO, to induce CPT1A degradation. Moreover, both constitutive and hepatocyte-specific ASB3 knockout enhance FAO and delay lipid accumulation, liver steatosis, and MASLD progression in a CPT1A-dependent manner. Hepatic ASB3 deficiency also delays fibrosis in MASLD. Analysis of public databases and liver tissue samples from MASLD patients revealed that ASB3 was highly expressed in MASLD patients and was negatively correlated with CPT1A.
Conclusions
Our study reveals the key roles of ASB3 in the development of MASLD and suggests a novel therapeutic potential for MASLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas
    Yueying Yang, Ying Yang, Yan Lu
    Clinical and Molecular Hepatology.2026; 32(2): 957.     CrossRef
  • The first genome-wide association study on pediatric obesity in Taiwan
    Hsin-Ru Wu, Ting-Yuan Liu, Chuan-Mu Chen, Fuu-Jen Tsai
    Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
  • Correspondence to editorial 1 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Yuli Lin, Dongqin Yang, Zhihao Wu, Ming Guan, Chunhua Song
    Clinical and Molecular Hepatology.2026; 32(3): e339.     CrossRef
  • Correspondence to editorial 2 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Dongqin Yang, Yuli Lin, Chunhua Song, Ming Guan
    Clinical and Molecular Hepatology.2026; 32(3): e342.     CrossRef
  • ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Ho Jae Ryu, Ji Su Han, Ja Hyun Koo
    Clinical and Molecular Hepatology.2026; 32(3): 1379.     CrossRef
  • A multi-herb botanical formula ameliorates diet-induced non-alcoholic fatty liver disease associated with microbiota-dependent metabolic remodeling in mice
    Xinrui Meng, Fan Wang, Ying Li, Yan Li, Meiping Zhang, Jing Cong
    Food Research International.2026; 243: 120383.     CrossRef
  • ASB3 limits adipocyte thermogenesis and energy expenditure through p62 ubiquitination
    Mengyu Shi, Haoye Liu, Zhihao Wu, Linlin Huang, Chunhua Song, Yuli Lin, Dongqin Yang
    Metabolism.2026; 184: 156756.     CrossRef
  • Transcriptome and 16S rRNA analysis reveal the regulatory mechanisms underlying the differences in fat deposition between distinct broiler breeds
    Fang Wang, Wei Jing, Yuyang Xue, Shanshan Nan, Jinchao Liang, Cunxi Nie
    Journal of Advanced Research.2026;[Epub]     CrossRef
  • 8,293 View
  • 577 Download
  • 6 Web of Science
  • Crossref
Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures
Yee Hui Yeo, Mengyi Zhang, Martin S. McCoy, Jian Zu, Yingli He, Yi Liu, Juan Li, Taotao Yan, Yuan Wang, Hirsh D. Trivedi, Ju Dong Yang, Vinay Sundaram, Xiaodan Sun, Zhujun Cao, Chun-Ying Wu, Jonel Trebicka, Fanpu Ji
Clin Mol Hepatol 2025;31(4):1355-1371.
Published online September 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.0573
Background/Aims
Prediction of short-term mortality in patients with acute-on-chronic liver failure (ACLF) admitted to the intensive care unit (ICU) may enhance effective management.
Methods
To develop, explain, and validate a predictive machine learning (ML) model for short-term mortality in patients with ACLF with two or more organ failures (OFs). Utilizing a large ICU cohort with detailed clinical information, we identified ACLF patients with two or more OFs according to the EASL-CLIF and NACSELD definitions. ML model was developed for each definition to predict 30-day mortality. The Shapley value was estimated to explain the models. Validation and calibration of these models were performed.
Results
Of 5,994 patients with cirrhosis admitted to ICU, 1,511 met NACSELD criteria, and 1,692 met EASL-CLIF grade II or higher criteria. The CatBoost ACLF (CBA) model had the greatest accuracy in the NACSELD cohort (area under curve [AUC] of 0.87), while the Random Forest ACLF (RFA) model performed best in the EASL-CLIF cohort (AUC of 0.83). Both models showed robust calibration. The models were explained by SHAP score analysis, yielding a rank list, and the top twelve predictors were selected. Both simplified models demonstrated similar performance (CBA model: AUC 0.89, RFA model: AUC 0.81) and significantly outperformed contemporary scoring systems, including CLIF-C ACLF and MELD 3.0. The models were validated in both internal and external cohorts. A simple-to-use online tool was created to predict mortality rates.
Conclusions
We presented explainable, well-validated, and calibrated predictive models for ACLF patients with two or more OFs, which outperformed existing predictive scores.

Citations

Citations to this article as recorded by  Crossref logo
  • Unbiased clustering of acute-on-chronic liver failure patients using machine learning in a real-world ICU cohort
    Mengyi Zhang, Fanpu Ji, Jian Zu, Yingli He, Tao Chen, Yi Liu, Hirsh D. Trivedi, Ju Dong Yang, Vinay Sundaram, Yuan Wang, Xiaodan Sun, Zhujun Cao, Chun-Ying Wu, Yee Hui Yeo, Rajiv Jalan
    Nature Communications.2026;[Epub]     CrossRef
  • Systematic evaluation of machine learning models for clinical risk prediction on real-world hospital datasets
    Qingwen Wu, Ziyou Qi, Qingwei Li, Cuiping Hao, Sujuan Tang
    iScience.2026; 29(5): 115654.     CrossRef
  • Navigating the therapeutic tightrope: Precision use of plasmapheresis and continuous renal replacement therapy in liver failure
    Manish Manrai, Aditya V Pachisia, Saurabh Dawra, Siddharth Shukla, Atul A Jha
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease
    Jonathan Soldera
    Diagnostics.2026; 16(10): 1548.     CrossRef
  • Gut–Liver Axis Failure in Critical Alcohol‐Associated Liver Disease: From ICU Secondary Hits to Microbiome‐Targeted Therapy
    Yuting Zhang, Yiyu Wang, Yong Yang, Hong Mei, Xinxin Liu, Yuanxiu He, Song Qin, Banghai Feng, Ranjitsinh V. Devkar
    Mediators of Inflammation.2026;[Epub]     CrossRef
  • A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index
    Yijun Zhang, Chunyan Li, Shaohui Su, Jilin Huang, Siyu Fu, Yong Zhang, Shanhong Tang
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Harmonized ACLF prognostication with explainable machine learning models: Traversing from counts to composition: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ fail
    Sagnik Biswas, Akash Roy
    Clinical and Molecular Hepatology.2026; 32(3): 1386.     CrossRef
  • Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
    Jung Hee Kim
    Clinical and Molecular Hepatology.2026; 32(3): 1383.     CrossRef
  • Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
    Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji
    Clinical and Molecular Hepatology.2026; 32(3): e346.     CrossRef
  • Metabolomics and Machine Learning Uncover 5′-Methylthioadenosine as a Metabolic Indicator of Mixed-Pattern Drug-Induced Liver Injury
    Jinghui Zhang, Hongchuan Liu, Qingrong Qiu, Kongcai Zhu, Xian Ding, Rui Zhao, Ting Hu, Zhuoling An
    Metabolites.2026; 16(9): 614.     CrossRef
  • Dynamic prediction of the development of extrahepatic organ failures in ICU patients with decompensated cirrhosis
    Yee Hui Yeo, Linjie Que, Mengyi Zhang, Jian Zu, Yuankai Wu, Dian-Jung Chiang, Tao Chen, Yu Shi, Yingli He, Fengping Wu, Feng Han, Qing-Lei Zeng, Yu-Chen Fan, Hirsh D. Trivedi, Xiaogang Xiang, Yadong Wang, Yu Chen, Ju Dong Yang, Jun Li, Rajiv Jalan, Fanpu
    eGastroenterology.2026; 4(3): e100463.     CrossRef
  • Machine learning model for ACLF risk in decompensated cirrhosis
    Liwen Chen, Peipei Ren, Yi Kang
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • 9,070 View
  • 477 Download
  • 12 Web of Science
  • Crossref
Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease
Manami Iida, Atsuko Higashida, Shuichi Ohtomo, Akihito Takeuchi, Ryo Miura, Yoshinari Asaoka, Naoshi Horiba, Akira Honda, Atsushi Tanaka
Clin Mol Hepatol 2025;31(4):1372-1383.
Published online September 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.0575
Background/Aims
Bezafibrate (BZF), a dual peroxisome proliferator-activated receptor/pregnane X receptor agonist, has demonstrated efficacy in combination with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Although one of the therapeutic effects of BZF is suppression of bile acid synthesis, its specific impact on bile acid synthesis pathways has not been thoroughly explored. This study investigated bile acid profiles, synthesis intermediates, and their associations with liver biochemistries in patients with PBC and PSC, and evaluated the impact of BZF treatment on these associations.
Methods
We enrolled 30 patients with PBC, 10 with PSC, and 30 control subjects. We measured total bile acids, bile acid components, plasma levels of 7α-hydroxycholesterol (7α-OH-C), 7α-hydroxy-4-cholesten-3-one (C4), and 27-hydroxycholesterol (27-OH-C) to assess the classic and alternative bile acid synthesis pathways and analyzed the association with liver biochemistries with and without BZF treatment.
Results
Total bile acid levels were elevated in PBC and PSC compared to controls, correlating significantly with liver biochemistries. BZF treatment significantly suppressed the classic pathway, as evidenced by reduced 7α-OH-C and C4 levels. However, 27-OH-C levels, possibly reflecting the alternative pathway activity, were not reduced in those with elevated liver biochemistries despite BZF treatment, suggesting incomplete suppression of alternative pathway in patients with suboptimal BZF response.
Conclusions
These findings indicate that while BZF effectively suppresses the classic pathway, alternative pathway activity may compromise its therapeutic efficacy in treatment-resistant cases, highlighting the need for novel therapies inhibiting the alternative pathway in patients with inadequate response to BZF.

Citations

Citations to this article as recorded by  Crossref logo
  • The effects of starter feed on intestinal fungi and non-targeted metabolomics of blood in calf yaks
    Hongzhuang Wang, Duojie Qingni, Qing He, Zhandui Pingcuo, Nan Jiang, Yanbin Zhu, Qiang Zhang, Guifang Liu, Guangming Sun, Yangji Cidan, Faisal Ayub Kiani, Dunzhu Luosang, Wangdui Basang
    BMC Microbiology.2026;[Epub]     CrossRef
  • Metabolic Signatures in Pericardial Fluid and Serum Are Associated with Long-Term Restenosis After Isolated Coronary Artery Bypass Grafting
    Xiaozheng Zhou, Lin Zheng, Zhiyong Du, Jiyuan Luo, Kun Hua, Xiubin Yang
    Journal of Clinical Medicine.2026; 15(9): 3436.     CrossRef
  • The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex
    Henry H. Nguyen, Mark G. Swain
    Clinics in Liver Disease.2026; 30(3): 571.     CrossRef
  • 6,148 View
  • 228 Download
  • 4 Web of Science
  • Crossref

Snapshot

Decoding platelet function in liver cirrhosis: A shift from quantity to quality
Vibhuti Jakhmola, Sukriti Baweja, Chhagan Bihari
Clin Mol Hepatol 2025;31(4):1384-1386.
Published online July 29, 2025
DOI: https://doi.org/10.3350/cmh.2025.0809
  • 6,443 View
  • 95 Download

Erratum